These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

384 related articles for article (PubMed ID: 17390060)

  • 1. Biological comparison of ovarian cancer resistant cell lines to cisplatin and Taxol by two different administrations.
    Yan XD; Li M; Yuan Y; Mao N; Pan LY
    Oncol Rep; 2007 May; 17(5):1163-9. PubMed ID: 17390060
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Comparison of stepwise and pulse induced cisplatin-resistant ovarian cancer cell sublines].
    Cheng G; Li Y; Tian F
    Zhonghua Zhong Liu Za Zhi; 2001 Jul; 23(4):305-8. PubMed ID: 11783113
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model.
    Horowitz NS; Hua J; Gibb RK; Mutch DG; Herzog TJ
    Gynecol Oncol; 2004 Jul; 94(1):67-73. PubMed ID: 15262121
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reversing drug resistance in the ovarian carcinoma cell line SKOV3/mdr1 in vitro by antisense oligodeoxynucleotides.
    Pan L; Tong Y; Jin Y; Zhou S; Zhang Y; Yang X; Mao N
    Chin Med J (Engl); 2001 Sep; 114(9):929-32. PubMed ID: 11780384
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reversal of multidrug resistance by small interfering double-stranded RNAs in ovarian cancer cells.
    Zhang T; Guan M; Jin HY; Lu Y
    Gynecol Oncol; 2005 May; 97(2):501-7. PubMed ID: 15863151
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Proteomic analysis of human ovarian cancer cell lines and their platinum-resistant clones].
    Yan XD; Pan LY
    Zhonghua Fu Chan Ke Za Zhi; 2006 Sep; 41(9):584-7. PubMed ID: 17181965
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Establishment of 5 resistant ovarian cancer cell strains and expression of resistance-related genes].
    Luan YZ; Li L; Li DR; Zhang W; Tang BJ
    Zhonghua Fu Chan Ke Za Zhi; 2004 Jun; 39(6):403-7. PubMed ID: 15312326
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The selection of taxol resistance associated genes in ovarian cancer cell line by mRNA DD].
    Cheng G; Tian F; Li Y
    Zhonghua Yi Xue Za Zhi; 2000 Jul; 80(7):541-3. PubMed ID: 11798816
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modulation of cisplatin resistance in acquired-resistant nonsmall cell lung cancer cells.
    Lai SL; Hwang J; Perng RP; Whang-Peng J
    Oncol Res; 1995; 7(1):31-8. PubMed ID: 7549042
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oxaliplatin in treatment of the cisplatin-resistant MKN45 cell line of gastric cancer.
    Tozawa K; Oshima T; Kobayashi T; Yamamoto N; Hayashi C; Matsumoto T; Miwa H
    Anticancer Res; 2008; 28(4B):2087-92. PubMed ID: 18751380
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Chemotherapy resistance induced by interleukin-6 in ovarian cancer cells and its signal transduction pathways].
    Wang Y; Li LZ; Ye L; Niu XL; Liu X; Zhu YQ; Sun WJ; Liang YJ
    Zhonghua Fu Chan Ke Za Zhi; 2010 Sep; 45(9):691-8. PubMed ID: 21092551
    [TBL] [Abstract][Full Text] [Related]  

  • 12. cis-diamminedichloroplatinum(II)-resistant sublines derived from two human ovarian tumor cell lines.
    Kuppen PJ; Schuitemaker H; van 't Veer LJ; de Bruijn EA; van Oosterom AT; Schrier PI
    Cancer Res; 1988 Jun; 48(12):3355-9. PubMed ID: 2897238
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Autocrine production of interleukin-6 confers cisplatin and paclitaxel resistance in ovarian cancer cells.
    Wang Y; Niu XL; Qu Y; Wu J; Zhu YQ; Sun WJ; Li LZ
    Cancer Lett; 2010 Sep; 295(1):110-23. PubMed ID: 20236757
    [TBL] [Abstract][Full Text] [Related]  

  • 14. P-glycoprotein expression in ovarian cancer cell line following treatment with cisplatin.
    Yang X; Pagé M
    Oncol Res; 1995; 7(12):619-24. PubMed ID: 8704279
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment with paclitaxel alone rather than combination with paclitaxel and cisplatin may be selective for cisplatin-resistant ovarian carcinoma.
    Yamamoto K; Kikuchi Y; Kudoh K; Hirata J; Kita T; Nagata I
    Jpn J Clin Oncol; 2000 Oct; 30(10):446-9. PubMed ID: 11185891
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of P-gp, MRP, LRP, GST-π and TopoIIα and intrinsic resistance in human lung cancer cell lines.
    Wang J; Zhang J; Zhang L; Zhao L; Fan S; Yang Z; Gao F; Kong Y; Xiao GG; Wang Q
    Oncol Rep; 2011 Nov; 26(5):1081-9. PubMed ID: 21805041
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization and resistance mechanisms of cisplatin-resistant human hepatocellular carcinoma cell line.
    Yang JX; Luo Y; Qiu HM; Tang WX
    Saudi Med J; 2009 Jan; 30(1):35-40. PubMed ID: 19139770
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of platinum-resistance associated proteins through proteomic analysis of human ovarian cancer cells and their platinum-resistant sublines.
    Yan XD; Pan LY; Yuan Y; Lang JH; Mao N
    J Proteome Res; 2007 Feb; 6(2):772-80. PubMed ID: 17269733
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Study of mdr1 antisense oligodeoxynucleotides on reversal of multidrug resistance in ovarian carcinoma cell line SKOV3].
    Tong Y; Pan L; Zhou S
    Zhonghua Fu Chan Ke Za Zhi; 2000 Nov; 35(11):677-9. PubMed ID: 11218898
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Knock-down of P-glycoprotein reverses taxol resistance in ovarian cancer multicellular spheroids.
    Xing H; Wang S; Weng D; Chen G; Yang X; Zhou J; Xu G; Lu Y; Ma D
    Oncol Rep; 2007 Jan; 17(1):117-22. PubMed ID: 17143487
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.